Xconomy

JANUARY 11, 2019

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P.

Pricing 97

Pricing Conference Report Help 97

Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. It even has a price guide.). million, with potentially $72 million over five years.

PMI 40

PMI Study Google Research 40

Xconomy

OCTOBER 28, 2016

THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases. The group filed shareholder resolutions with 11 companies and cited a Kaiser Family Foundation poll that cited Americans’ concerns over drug prices.

Pricing 40

Pricing Conference News Study 40

Xconomy

SEPTEMBER 9, 2016

—Allergan CEO Brent Saunders criticized “egregious price takers” and pledged his own firm would practice responsible pricing to get out in front of potential legislative action that Democratic presidential candidate Hillary Clinton has been threatening.

Pricing 40

Pricing News Startup Screening 40

Xconomy

MARCH 16, 2018

Drug prices are top of mind for many patients. Some of them have to cut back on basic needs just to pay for treatments that seem to rise in price each year. The Tarrytown, NY, drugmaker plans to cut the price of its cholesterol-lowering drug alirocumab (Praluent) if it can get concessions from payers.

Pricing 59

Pricing Study San Diego Blogging 59

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. The first was Eidos Therapeutics (NASDAQ: EIDX ), which raised $106 million in its stock market debut.

Study 72

Study Startup Pricing Funding 72

Xconomy

MARCH 17, 2017

The data, from a massive study of more than 27,000 patients, come at a time when drug and healthcare prices are a top U.S. political issue, and pricey new cholesterol drugs have been a key battleground.

Study 87

Study Pricing Sales Journal 87

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. There were plenty of policy and drug-price headlines, Read more » Reprints | Share: After the deals, we’ll move on to data.

Study 55

Study Conference Pricing Marketing 55

Both Sides of the Table

MARCH 21, 2013

I recently wrote a blog post in which I pointed out that many investors & advisors discourage enterprise startups from having a professional services (PS) business and I think this is a big mistake. This might mean helping customers buy traffic, arb’ing deals, helping with RTB pricing or trading, etc.

Software Review 321

Software Review Software Services Company 321

InfoChachkie

DECEMBER 8, 2011

I began our discussion by asking Brad what motivated him to co-author Venture Deals , rather than continuing to share venture capitalists’ secrets via his Ask The VC blog. Writing a book is very different from writing a blog. In my review of the book, my biggest concern was the rather elevated list price of $49.95.

Venture Capital 224

Venture Capital Writing Entrepreneur Blogging 224

Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

APRIL 21, 2017

Our own reporting focused this week on the fallout from high drug prices, with a look at the frustration of families whose children have had trouble gaining access to the first drug ever approved for the rare spinal muscular atrophy.

Study 49

Study News Pricing Google 49

Both Sides of the Table

JANUARY 11, 2014

We go through case studies like how Mint.com & Magento drove large audiences through great content marketing strategies. I tell people that they need to blog about their industry to drive customers and not blog to their egos to drive their peer group to their blogs. Well, you have to do that, too.

Technical Review 384

Technical Review SEM SEO Marketing 384

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

OCTOBER 7, 2016

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. PRICE FIGHTS. With some caveats, ICER recommended lower prices. She refused to discuss Edison at the time. —The U.S.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

SEPTEMBER 20, 2019

Meanwhile, try to find someone in the federal government who isn’t involved in the drug-price debate. Health concerns about vaping continue to mount, and the feds could get involved.

Pricing 61

Pricing News Capital San Diego 61

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. The Nitto drug is in a Phase 1b study. Now, the U.S.

Patents 87

Patents Study Pricing Technical Review 87

Both Sides of the Table

NOVEMBER 14, 2010

I pointed to several Economist articles I had read that mapped historical prices of real estate for 400 years and how on average property values grow at no more 1.5% above inflation yet in many markets in the US & Europe prices were rising at 10-25% per year. And it’s driving up prices beyond their inherent value.

Invest 299

Invest Angel Technical Review Venture Capital 299

Both Sides of the Table

NOVEMBER 4, 2010

First, over time Salesforce.com’s technology got better and better yet the price didn’t shoot up dramatically relative to Siebel. They have existing customers who already paid big prices who would be seriously pissed off if the next guy bought the same thing for 10x less. They are radically lower in price.

Startup 376

Startup Framework Marketing Custom 376

Xconomy

FEBRUARY 27, 2017

La Jolla Pharmaceutical’s experimental drug to treat a deadly blood pressure condition hit its main goal in a Phase 3 clinical trial, boosting the company’s stock price by more than 75 percent on Monday morning.

San Diego 40

San Diego Study Pricing Organization 40

Xconomy

DECEMBER 20, 2016

San Diego-based Acadia (NASDAQ: ACAD ) reported that patients treated in an exploratory study with its drug pimavanserin showed a statistically significant reduction in psychosis compared against a group given a placebo. Investors cheered the news, boosting Acadia’s stock price 13.6 percent to $28.88 in trading Tuesday morning.

San Diego 40

San Diego Statistics Study News 40

Both Sides of the Table

SEPTEMBER 8, 2009

I was reading Chris Dixon’s blog tonight. I came across this blog post about getting a computer science degree as the best degree for getting into venture capital or working at a VC-backed start up. I also know many people who never studied business as an undergrad who appreciated the knowledge that they gained as an MBA.

Startup 337

Startup Venture Capital Study Course 337

Xconomy

MARCH 9, 2018

Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know the federal government is willing to push.

Pricing 56

Pricing Class Sales Marketing 56

Xconomy

JUNE 21, 2019

The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal cancer. Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma.

Study 58

Study San Diego Pricing Google 58

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. This time, he increased the price from $13.50 The Leerink analysts placed a $32 per share price target on the stock. to $30 apiece.

San Diego 40

San Diego Pricing Study Journal 40

Both Sides of the Table

APRIL 30, 2011

In the IAB study that revealed the graph above, brand advertisers indicated that their number one objective in online advertising was “creating awareness&# followed by “creating purchase intent&# or “likelihood to recommend&# the product. Give people massive price increases on most media and they’ll abandon it.

Advertising 352

Advertising Media Social Media Screening 352

Tech Zulu Event

MARCH 2, 2013

Providers make their pricing model transparent and easily available on the web, so it’s simple to calculate the cost savings of the cloud. Providers make their pricing model transparent and easily available on the web, so it’s simple to calculate the cost savings of the cloud.

Cloud Computing 85

Cloud Computing Marketing CIO Organization 85

Xconomy

SEPTEMBER 1, 2017

billion, the price Gilead Sciences is paying for Kite Pharma and its cancer-fighting cell therapy pipeline. The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9

Pricing 74

Pricing Ideas San Diego Study 74

Xconomy

JULY 8, 2016

British medical journal The Lancet published a study , funded by the Bill and Melinda Gates Foundation, that showed viral hepatitis has become the seventh leading cause of death globally, up from tenth in 1990. The FDA has halted the trial , and Juno’s share price dropped 28 percent after hours on Thursday.

News 52

News Pricing Journal Startup 52

Both Sides of the Table

OCTOBER 22, 2010

He studied the errors that other people had made and tried to improve on them. He wanted to create awareness for himself to generate marketing buzz and demand and then get the retail stores to pay wholesales prices for his cds. He’s holding back for now, but he’s clearly studying what’s going on in technology.

Entrepreneur 356

Entrepreneur Venture Capital Startup Email 356

Xconomy

APRIL 20, 2018

The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. While pembrolizumab notched the headline-grabbing data, others are also working to develop options for various subsets of patients. Who will be able to afford all these options?

Pricing 52

Pricing News Report Develop 52

Both Sides of the Table

AUGUST 12, 2010

But this gets all the space on prominent blogs because it’s what bloggers like to cover.&# It’s self selecting. A recent study said seed stage valuations have been quite static recently. Prices are creeping up and angels are feeling bullish. This created a big gap for people to come in. Minutes 11-13.

Venture Capital 232

Venture Capital Slides Seed Funding Google 232

Xconomy

AUGUST 11, 2017

The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices. Meanwhile, drug-price hawks can sharpen their talons on a report this week from The New York Times and ProPublica.

Pricing 52

Pricing News Report Competition 52

Xconomy

JUNE 10, 2016

BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

InfoChachkie

OCTOBER 3, 2011

Like music, movies and blog entries, startups are a remix of that which came before. As noted in What Color Are Your Elephant’s Sunglasses , the large majority of research and development expenditures are spent on product features (e.g., smaller, faster, cheaper, lighter, etc.)

Startup 255

Startup High Tech SaaS .Net 255

Xconomy

JULY 18, 2016

In early trading Monday, Evoke’s (NASDAQ: EVOK ) stock price was down 72 percent to $3.02 Evoke’s late-stage study failed to show a significant benefit to the drug, EVK-001, versus placebo at all 41 of the sites that tested it nationally. per share as of 11:30 a.m. in New York.

Study 40

Study Sites News Research 40

Xconomy

SEPTEMBER 2, 2016

The companies—Amgen, Sanofi, and Regeneron Pharmaceuticals—are due to release important long-term data next year that will shape the debate over the drugs’ prices. . —Staying in San Diego, Synthetic Genomics reported in Nature Methods that its scientists have re-engineered the salt-marsh-loving bacterium V.

News 57

News San Diego Journal Technical Review 57